Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands

被引:43
作者
Hanemaaijer, Susan [1 ,2 ]
Sodihardjo, Fong [1 ]
Horikx, Annemieke [1 ]
Wensing, Michel [3 ]
De Smet, Peter A. G. M. [1 ,4 ]
Bouvy, Marcel L. [2 ]
Teichert, Martina [1 ,3 ]
机构
[1] Royal Dutch Pharmacists Assoc KNMP, NL-2514 JL The Hague, Netherlands
[2] Univ Utrecht, Fac Sci, Utrecht Inst Sci, Div Pharmacoepidemiol & Clin Pharmacol, NL-3508 TB Utrecht, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept IQ Healthcare, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6500 HB Nijmegen, Netherlands
关键词
Adherence; DOACs; Drug use patterns; Netherlands; NOACs; Non-vitamin K oral anticoagulants; ATRIAL-FIBRILLATION PATIENTS; TASK-FORCE; WARFARIN; PERSISTENCE; DABIGATRAN; MANAGEMENT; RIVAROXABAN;
D O I
10.1007/s11096-015-0174-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Non-vitamin K oral anticoagulants (NOACs) became available in the Netherlands in 2008, providing another antithrombotic treatment besides vitamin K antagonists (VKAs) and antiplatelet agents (APAs). Objective To describe the patterns of antithrombotic drug use between 2008 and 2013 by examination of dispensing data form community pharmacies in the Netherlands; to determine the concomitant use of NOACs with VKAs and APAs and switching between the drug classes; and to compare adherence to NOACs with adherence to APAs. Setting An observational retrospective study was conducted using routinely collected dispensing data from Dutch community pharmacies. Methods For each calendar year, the numbers of NOAC, VKA, and APA users were calculated. Adherence was determined for NOACs and APAs by the percentage of days covered by medication (PDC). Information on the prescribed daily dose of VKAs was unavailable. Main outcome measures Comparison of age, sex, and co-medications of users of the three drug classes; concomitant use of different antithrombotic drug classes and switching between these in each year; and mean PDC and percentages of all users with a PDC above 80 %. Results NOAC use increased during the study period to 29,687 users in 2013. In that year there were 484,024 VKA users and 1313,032 APA users. Compared with users of VKAs, NOAC users were slightly younger and more frequently used antiarrhythmic drugs and beta blockers as co-medications. Substantial numbers of patients were dispensed potentially harmful combinations in 2013: 820 subjects were dispensed NOACs together with VKAs, and 684 subjects were dispensed NOACs, VKAs, and APAs concomitantly. Mean adherence to NOACs was 84.2 % compared with 87.3 % to APA. One in four NOAC users had a PDC lower than 80 % compared with one in five APA users. Conclusion Our findings show increasing use of NOACs by outpatients. The number of patients taking potentially harmful combinations of antithrombotic drugs was substantial. Adherence to NOACs in daily practice may be suboptimal to prevent thrombotic events.
引用
收藏
页码:1128 / 1135
页数:8
相关论文
共 50 条
  • [31] Stroke Prevention with Non-Vitamin K Oral Anticoagulants: For Most, but Not for All!
    Steffel, Jan
    CARDIOLOGY, 2019, 143 (3-4) : 121 - 123
  • [32] The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time
    Negro, Francesco
    Caravelli, Paolo
    Morganti, Riccardo
    Casini, Monica
    Ruocco, Lucia
    Tripodi, Armando
    De Caterina, Raffaele
    VASCULAR PHARMACOLOGY, 2022, 144
  • [33] Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation
    Rivera-Caravaca, Jose Miguel
    Asuncion Esteve-Pastora, Maria
    Roldan, Vanessa
    Marin, Francisco
    Lip, Gregory Y. H.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (09) : 1051 - 1062
  • [34] Oral Anticoagulation Update on Anticoagulation With Vitamin K Antagonists and Non-Vitamin K-Dependent Oral Anticoagulants
    Altiok, Ertunc
    Marx, Nikolaus
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (46): : 776 - 783
  • [35] Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study
    Basaran, Ozcan
    Dogan, Volkan
    Beton, Osman
    Tekinalp, Mehmet
    Aykan, Ahmet Cagri
    Kalaycioglu, Ezgi
    Bolat, Ismail
    Tasar, Onur
    Safak, Ozgen
    Kalcik, Macit
    Yaman, Mehmet
    Inci, Sinan
    Altintas, Bernas
    Kalkan, Sedat
    Kirma, Cevat
    Biteker, Murat
    Karadeniz, Fatma Ozpamuk
    Tekkesin, Ahmet Ilker
    Cakilli, Yasin
    Turkkan, Ceyhan
    Hamidi, Mehmet
    Demir, Vahit
    Gursoy, Mustafa Ozan
    Ozturk, Mujgan Tek
    Aksan, Gokhan
    Seyis, Sabri
    Balli, Mehmet
    Alici, Mehmet Hayri
    Bozyel, Serdar
    Altun, Ibrahim
    Calik, Feyza
    Karaca, Oguz
    Helvaci, Fusun
    Akay, Kadriye
    Canga, Yigit
    Celebi, Savas
    Altuntas, Emine
    Ayturk, Mehmet
    Gunes, Haci Murat
    Bezgin, Tahir
    Aksakal, Aytekin
    Cakal, Beytullah
    Colak, Ayse
    Kaplan, Ozgur
    Tatlisu, Adem
    Gozubuyuk, Gokhan
    Demirelli, Selami
    Kaya, Adnan
    Rencuzogullari, Ibrahim
    Bayram, Zubeyde
    MEDICINE, 2016, 95 (35)
  • [36] Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
    Bisson, Arnaud
    Angoulvant, Denis
    Philippart, Raphael
    Clementy, Nicolas
    Babuty, Dominique
    Fauchier, Laurent
    ADVANCES IN THERAPY, 2017, 34 (06) : 1283 - 1290
  • [37] Non-vitamin K antagonist oral anticoagulants for heart diseases
    Kondratieva, T. B.
    Popova, L. V.
    Bokarev, I. N.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (09) : 120 - 127
  • [38] Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
    Sciascia, Savino
    Lopez-Pedrera, Chary
    Cecchi, Irene
    Pecoraro, Clara
    Roccatello, Dario
    Cuadrado, Maria Jose
    RHEUMATOLOGY, 2016, 55 (10) : 1726 - 1735
  • [39] Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
    Li, Wenhao
    Zhou, Yanxia
    Chen, Siqi
    Zeng, Dewang
    Zhang, Haidong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [40] Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
    Thomas Gremmel
    Alexander Niessner
    Hans Domanovits
    Martin Frossard
    Gürkan Sengölge
    Barbara Steinlechner
    Thomas Sycha
    Michael Wolzt
    Ingrid Pabinger
    Wiener klinische Wochenschrift, 2018, 130 : 722 - 734